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Background  and  aims:  GP-TCM  is  the 1st  EU-funded  Coordination  Action  consortium  dedicated  to tradi-
tional  Chinese  medicine  (TCM)  research.  This  paper  aims  to  summarise  the  objectives,  structure  and
activities  of  the  consortium  and introduces  the  position  of  the  consortium  regarding  good  practice,
priorities,  challenges  and  opportunities  in TCM  research.  Serving  as  the  introductory  paper  for  the GP-
TCM Journal  of Ethnopharmacology  special  issue,  this  paper  describes  the  roadmap  of this  special  issue
and  reports  how  the  main  outputs  of the  ten  GP-TCM  work  packages  are  integrated,  and  have  led  to
consortium-wide  conclusions.
Materials  and methods:  Literature  studies,  opinion  polls  and  discussions  among  consortium  members  and
stakeholders.
Results:  By  January  2012,  through  3 years  of  team  building,  the  GP-TCM  consortium  had  grown  into  a
large  collaborative  network  involving  ∼200  scientists  from  24  countries  and  107  institutions.  Consortium
members  had  worked  closely  to  address  good  practice  issues  related  to various  aspects  of  Chinese  herbal
medicine  (CHM)  and  acupuncture  research,  the focus  of this  Journal  of Ethnopharmacology  special  issue,
leading  to  state-of-the-art  reports,  guidelines  and  consensus  on the  application  of omics  technologies
in  TCM  research.  In  addition,  through  an  online  survey  open  to GP-TCM  members  and  non-members,
we  polled  opinions  on grand  priorities,  challenges  and  opportunities  in  TCM research.  Based  on the
poll,  although  consortium  members  and  non-members  had  diverse  opinions  on  the  major  challenges  in
eed  that  high-quality  efﬁcacy/effectiveness  and mechanistic  studies  are  grandthe ﬁeld,  both  groups  agr
priorities  and that  the  TCM  legacy  in  general  and  its  management  of  chronic  diseases  in  particular  rep-
resent  grand  opportunities.  Consortium  members  cast  their  votes  of  conﬁdence  in omics  and  systems
biology  approaches  to  TCM  research  and  believed  that  quality  and  pharmacovigilance  of TCM  products  are
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ra;  GxP, good practice guidelines; R&D, research and development; TCM, traditional Chinese medicine; WP,  work package.
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not  only  grand  priorities,  but  also  grand  challenges.  Non-members,  however,  gave  priority  to  integra-
tive  medicine,  concerned  on the  impact  of  regulation  of  TCM  practitioners  and  emphasised  intersectoral
collaborations  in  funding  TCM  research,  especially  clinical  trials.
Conclusions:  The  GP-TCM  consortium  made  great  efforts  to  address  some  fundamental  issues  in TCM
research,  including  developing  guidelines,  as well  as  identifying  priorities,  challenges  and  opportunities.
These consortium  guidelines  and  consensus  will  need  dissemination,  validation  and  further  development
through continued  interregional,  interdisciplinary  and intersectoral  collaborations.  To  promote  this,  a
new  consortium,  known  as  the  GP-TCM  Research  Association,  is  being  established  to  succeed  the 3-year
ﬁxed  term  FP7  GP-TCM  consortium  and  will  be ofﬁcially  launched  at the  Final  GP-TCM  Congress  in  Leiden,
the  Netherlands,  in  April  2012.
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a. GP-TCM
.1. What is GP-TCM?
GP-TCM is the acronym of good practice in traditional Chinese
edicine research in the post-genomic era.  It was  the ﬁrst EU-
unded 7th Framework Programme (FP7) Coordination Action1
iming to inform the best practice and harmonise research into
CM through interregional, interdisciplinary and intersectoral col-
aboration (Uzuner et al., 2010). The overall aims of GP-TCM were
s follows:
To develop a European-Chinese network collaborating on TCM
research, with an emphasis on the application of omics technolo-
gies.
To review current practice of TCM research, identifying problems
and proposing solutions.
To propose standard protocols on methodology.
To propose priority areas for future research.
To develop online resources to support and enhance pan-
European studies of TCM research.
To facilitate and foster a sustainable European collaboration by
founding an academic association to carry on the missions of GP-
TCM.
By January 2012, the consortium had 29 beneﬁciary (i.e. funded)
nd 78 non-beneﬁciary (i.e. unfunded) partner institutions in 24
ountries, including 15 EU member states and 9 non-EU coun-
ries (Fig. 1.1). The consortium partnership spanned across both
he public (∼80%) and private sectors (∼20%) and all members
ad a proven track record and an international reputation in TCM
esearch.
.2. GP-TCM work packages (WPs)
GP-TCM comprised 10 interactive WPs  (Fig. 1.2). WPs  1–7
ocused on Chinese herbal medicine (CHM) research, WP8  dealt
ith acupuncture and WP9  was dedicated to the coordination
f meetings and events. As the overall management team of the
onsortium, WP10 coordinated WP  leadership, membership and
ollaboration, steered research direction, organised quality assur-
nce and was in charge of collation, integration and dissemination
f results. The authors of this paper are a subgroup of WP10 mem-
ers and we aim to highlight the main achievements of each WP  and
eport how these outputs were integrated and how consortium-
ide conclusions were drawn.
1 A sub-category of FP7 projects, aiming to promote and support the networking
nd coordination of research innovation activities.© 2012 Elsevier Ireland Ltd. 
1.3. What is meant by “good practice” in the GP-TCM consortium?
Good practice was the soul of the GP-TCM consortium. However,
determining what was  good practice was a highly subjective exer-
cise without a clear deﬁnition or standard indicators or guidelines
for evaluation and monitoring.
Broadly, good practice was deﬁned as compliance with the
European Charter for Researchers, the European Agency for Safety
and Health at Work Guidelines,  commonly accepted guidelines for
medical research, such as the Wellcome Trust Guidelines on Good
Research Practice, as well as a deﬁnition of good practice from the
European Institute for Comparative Cultural Research. In addition,
due to the speciﬁc characteristics and wide range of research topics
involved in GP-TCM, we  further deﬁned good practice as follows:
1.3.1. Technically, it was GxP (good practice guidelines)
GxP meant good practice guidelines at every stage of TCM
research and development, focusing on research into acupuncture
and CHM, and including Good Agriculture and Collection Practice,
Good Laboratory Practice, Good Research Practice, Good Manu-
facturing Practice, Good Clinical Practice, and Good Information
Technology Practice, Good Literature Review and Publication Prac-
tice, etc. These GxP items are key themes of other papers in this
special issue.
1.3.2. Strategically, it was collaboration and sharing
To address speciﬁc deliverables, i.e. the research objectives
agreed between the consortium and the European Commission,
GP-TCM members were encouraged to collaborate closely, starting
with agreement on a series of deliverable-related central questions,
followed by job assignment, literature studies, sharing knowledge
and resources, as well as constructive discussions. To develop easy-
to-follow guidelines to support the whole consortium, a Literature
Review Good Practice Panel was  established to identify common
problems, conduct focused discussions and propose solutions. The
Panel and management team organised regular online and face-
to-face meetings to share what had been learnt and to improve
transferability and practicality of good practice guidelines as they
were developed.
1.3.3. Practically, it was consensus while respecting differences of
opinion
In GP-TCM discussions, the consortium valued every member’s
opinions and thus was  keen to receive any internal and external
evidence to support improving guidelines and deﬁne even better
practice. We  appreciated the critical importance of disseminating
our research outcomes and receiving feedback from broader
scientiﬁc communities and stakeholders. In particular, we were
in liaison with a number of key stakeholders and international
organisations such as the European Directorate for the Quality
of Medicines & Healthcare TCM Working Party, the European
Open access under CC BY-NC-ND license.Medicines Agency Committee on Herbal Medicinal Products,
the China State Administration of TCM, the Chinese Pharma-
copoeia TCM Commission, and the Consortium for Globalization of
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tig. 1.1. Distribution of GP-TCM members within and beyond the EU. (A) Fifteen EU
inland, Germany, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Romania,
nvolved  in GP-TCM, including Australia, Burkina Faso, Canada, China, D.R. Congo, N
hinese Medicine (CGCM). As research into many other systems
f traditional medicines equally needs good practice guidelines,
e also collaborated with many colleagues outside the EU and
hina, including the U.S. Food and Drug Administration Botanical
eview Team. When we  dealt with consensus and controversy
n any internal and external affairs, we followed the principle of
nding common grounds while respecting differences..4. Why  was omics of special interest?
TCM has been used by Chinese and other Asian people for
housands of years to maintain the health of one of the biggest
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populations in the world (Normile, 2003). In TCM, CHM and
acupuncture were the most commonly used and thus each formed
a focus for GP-TCM. In recent years, TCM has been used by an
increasing number of people in Europe (Fisher and Ward, 1994;
Uzuner et al., 2010; Dobos and Tao, 2011). However, in contrast
to the reductionist approach of Western medicine that is based on
anatomy, physiology, pharmacology, cell and molecular biology,
TCM is based on thousands of years of recorded clinical experience,
guided by Chinese philosophy, e.g. the Yin-Yang theory empha-
sising the balance of functional systems. TCM uses a theoretical
system with a personalised and holistic approach to describe
health and disease (Normile, 2003). Speaking in metaphors, while
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estern medicine tends to see trees but not the wood, TCM, on
he other hand, often sees the wood but not the trees. Therefore,
oth systems can learn from each other.
Fortunately, by the end of the ﬁrst decade of the new mil-
ennium, when the GP-TCM consortium was initiated, omics and
ystems biology technologies started to emerge as a novel but
aturing means of observing organisms, including their indica-
ors of health and disease, at the molecular level. With these
echniques, it seems possible that the holistic and personalised
CM and the post-genomic Western medicine, which is striv-
ng for greater personalisation and holistic and pre-emptive
pproaches, have ﬁnally found a common ground. The suf-
x omics is deﬁned here as a synonym for various technical
pproaches of the post-genomic era, addressing whole proﬁles of
NA (genomics), mRNA (transcriptomics), proteins (proteomics),
etabolites (metabolomics/metabonomics) through comprehen-
ive bioinformatics-based analysis (Joyce and Palsson, 2006). These
echnologies allow information-rich and high-throughput molec-
lar observations, aiming to link them to biologically and clinically
elevant functions using a systems biology approach. Therefore, the
ope is that omics technologies and a systems biology approach
ay  be especially suitable for addressing and investigating TCM in
 holistic manner (Verpoorte et al., 2005; Wang et al., 2005).
. The GP-TCM Journal of Ethnopharmacology special issue
.1. Objectives
Since 1st May  2009, the 10 GP-TCM WPs  have worked diligently
ogether on literature searches and discussions of good practice
ssues. To summarise the research outcomes and recommendations
rom all GP-TCM WPs  in a way convenient for future reference, we
ecided to prepare a series of publications derived from the GP-
CM consortium to be collated into a special issue of the Journal of
thnopharmacology.
.2. Roadmap
The special issue comprised 1–3 papers contributed by every
P-TCM WP  and 4 independent papers complementary to the work
f GP-TCM WPs  (Fig. 1.3).
.3. Contributions from GP-TCM WPs
.3.1. WP1
WP1  specialised in the quality control of CHM, an important
rea that has been reviewed recently (Pferschy-Wenzig and Bauer,
009; Bauer and Franz, 2010). In this special issue, WP1  contributed
o two papers. The ﬁrst is the outcome from a joint effort of WP1
nd WP10 (the GP-TCM Literature Review Good Practice Panel) and
ocuses on good practice in reviewing and publishing studies of
erbal medicines, especially on the problems involved in naming
lant species within CHM (Chan et al., 2012). The second paper sys-
ematically introduces “Daodi” Chinese materia medica (CMM), a
opular TCM concept with important clinical, cultural and scientiﬁc
mplications (Zhao et al., 2012).
.3.2. WP2
WP2  specialised in extraction and chemical analysis of CHM. The
P2  paper deals with both raw herbs and processed materials and
ives recommendations for (i) the application of modern extrac-
ion techniques for the development of improved CHM drugs; (ii)
inimum acceptable standards for extract characterisation for sci-
ntiﬁc publications; (iii) general experimental approaches whichmacology 140 (2012) 458– 468 461
aim to identify active (maybe synergetic) components and analyt-
ical markers for quality control (Sheridan et al., 2012).
2.3.3. WP3
WP3  specialised in studying all aspects of the toxicology of CHM.
The WP  contributes three papers, one describing the state of the art
of a series of toxicological studies with their applications to CHM
and the other two focusing on pharmacovigilance of herbal use in
China and in the West, respectively. In vitro and in vivo techniques,
including omics approaches, for the detection of genotoxicity, ter-
atogenicity and nephrotoxicity, were analysed. Techniques and
prototype toxicants (“prototoxicants”) were reviewed to investi-
gate what was available in terms of methods and strategies to
evaluate but also to predict toxicities (Ouedraogo et al., 2012). The
characteristics of CHM and other TCM drugs pose particular chal-
lenges to pharmacovigilance both in China and in the West, which
were highlighted by Shaw et al. (2012) and Zhang et al. (2012).
2.3.4. WP4  and WP5
WP4  specialised in the in vitro and in vivo pharmacology of CHM,
respectively. WP4  and WP5  contribute three papers, one focussing
on in silico studies of CHM, another on in vitro and in vivo studies
of CHM using an omics approach and the third on animal studies
of CHM. The former offers a state-of-the-art critical review of the
available TCM databases, in terms of their contents and utility for in
silico research on CHM, and provides recommendations for future
in silico studies of CHM (Barlow et al., 2012). The second paper is
a collaboration between WP4  and WP5  members. It reviews the
published work on omics and systems biology studies of CHM and
discusses the pros and cons for using omics and systems biology
approaches in CHM research (Buriani et al., 2012). The third paper
is an overview of the status quo and problems in animal studies
of CHM based on a Medline-based literature analysis, which has
provided a checklist to help readers and authors to collect impor-
tant information required to ensure reproducibility of CHM animal
studies (Garcia et al., 2012).
2.3.5. WP6
WP6  was dedicated to clinical studies of CHM. It offers two
papers: The ﬁrst focuses on a comparison between granules and
decoctions (Luo et al., 2012). This is the ﬁrst systematic review
comparing the effectiveness and safety of granules to the more
traditional method of prescribing herbal decoctions, and was a
response by the consortium to investigate the increasing clinical
use of CHM granules in recent years. The second paper introduces
expert recommendations on conducting randomised controlled tri-
als to investigate CHM, which not only offers guidelines on running
randomised clinical trials of CHM and on discussing research ques-
tions with different clinical trial modalities, but also comments on
the challenges of relating omics studies to clinical trials (Flower
et al., 2012).
2.3.6. WP7
WP7  was  dedicated to industrial R&D and regulatory aspects of
CHM. Two  papers have been contributed by this WP.  The ﬁrst paper
provides a comprehensive comparison of the respective practices
of different countries in the regulation of CHM and other complex
herbal products (CHP) and has successfully formulated an easy-
to-follow procedures for the various regulatory frameworks in a
selection of the biggest markets of CHM and other CHP (Fan et al.,
2012). The second paper describes current research outcomes for
the application of omics technologies in the broad ﬁeld of regula-
tory sciences and discusses the implications of such research on
the future R&D and regulation of CHM and CHP. It suggests that
the ever-increasing thrust of omics techniques and their integra-
tion through a systems biology approach in the regulatory studies
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WP10 
No.1 – Good practice and grand issues in TCM research 
No. 2 – Good practice in reviewing and publishing TCM literature 
WP8 
No. 14 –  Omics and acupuncture
No. 15 – Acupuncture: A  survey on clinical 
practice in Europe and China 
WP1/WP2 
No. 3 –  Daodi  Chinese material  medica
No. 4 – Extraction and chemical analysis of CHM/complex herbal products (CHP) 
WP3 
No. 5 –  Toxicological methods and 
toxicology of selected CHM
No. 6 – Pharmacovigilance  in China
No. 7 – Pharmacovigilance  in the  West
WP4 and WP5 
No. 8 – In silico  studies of CHM 
No. 9 – Omics in CHM studies, in vitro and in 
vivo 
WP6 
No. 10 –  Guidelines for  randomised controlled trials 
No. 11 – Comparison between decoctions and granules 
WP7 
No. 12 – Regulation of CH P worldwide
No. 13 – Omics in regulatory science and 
Implications to CHP
Independent contributions 
No. 16 – PHY906 in the US, complementary to WPs 1-7 
No. 17 –  Value formation of herbal products, complementary to WPs 1-7 
No. 18 – TCM syndrome differentiation, complementary to all WPs 1-8 
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pFig. 1.3. Roadmap of
f conventional medicines may  eventually lead to a convergence
nd integration with CHM (Pelkonen et al., 2012).
.3.7. WP8
WP8  was the only WP  focusing on acupuncture. WP8  con-
ributes two papers to this special issue. The ﬁrst paper summarises
urrent scientiﬁc understanding of the acupuncture meridian sys-
em and acupoints. It comments on advances in basic research
n acupuncture/moxibustion-related studies and suggests future
trategies and approaches in the application of omics techniques
nd a systems biology approach to this speciﬁc research area (Jia
t al., 2012). The second paper describes the results of a survey of
ractitioners of traditional acupuncture in the EU and China. It was
arried out to identify differences in acupuncture practice, educa-
ion and training, which might inﬂuence the methodologies used
nd outcomes of international multi-centre clinical trials. Acupunc-
urists’ perceived need for research evidence and prioritisation for
uture clinical trials was identiﬁed (Robinson et al., 2012).
.3.8. WP9  and WP10
WP9  was in charge of organising two meetings to take place in
he Netherlands at the end of the project. The ﬁrst meeting, known
s the GP-TCM Final Conference (12th–13th April 2012), would
erve as the concluding meeting of the consortium, allowing mem-
ers and stakeholders to have face-to-face discussions to ﬁnalise
he conclusions of each WP  and the whole consortium. The second
eeting, known as the GP-TCM Congress (15th–18th April 2012),
ould serve as a dissemination opportunity for the consortium and
ould be open to the public.
WP10 was the management WP  of the consortium, in charge ofollation and integration of data to draw consortium-wide conclu-
ions. In addition to this introductory paper, the Literature Review
ood Practice Panel, an important part of WP10, contributed a
aper in collaboration with WP1, focusing on good practice inP-TCM special issue.
reviewing and publishing studies of herbal medicines, especially
CHM (Chan et al., 2012).
2.4. Contributions complementary to the work of GP-TCM WPs
Due to the Coordination Action nature of the GP-TCM project
and its limited funding, manpower and lifespan, some very
important issues of TCM were not directly covered by GP-TCM
deliverables and central questions. To complement the strength of
the GP-TCM papers to provide a more comprehensive and balanced
view of this special issue, we  invited some GP-TCM members to
share their practical experiences in areas not extensively covered
by existing papers. For instance, R&D of CHM is a long journey,
along which nearly all focused areas of research of the GP-TCM
consortium must be integrated successfully in order to bring a CHM
product onto the market, including quality control and component
analysis (WP1 and WP2), toxicology (WP3), in vitro and in vivo
pharmacology (WP4 and WP5), clinical trials (WP6) and industrial
R&D to meet regulatory requirements (WP7). To best illustrate this
interdisciplinary process, we have invited Liu and Cheng (2012)
to share their invaluable experiences in the USA of developing
a four-herb formulation with over 1800 years of history into a
new adjuvant therapy for cancer patients using chemotherapy. The
PhytomicsQC platform that they have developed to integrate con-
ventional and omics approaches to achieve comprehensive quality
control and the way that they have conducted their preclinical and
clinical studies and interacted with regulatory bodies should serve
as an excellent example for colleagues in Europe and worldwide.
Importantly, their ten years of successful journey, together with
some others (Xu, 2011), has clearly unveiled a novel paradigm
to develop standardised CHM granules into advanced botanical
drugs, an approach that represents a new direction towards inno-
vation in the pharmaceutical industry, which may  contribute to
growth in the global economy. Thus, although GP-TCM mainly
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ocused on natural and biological sciences of TCM, the cultural,
ocial and economic signiﬁcance of TCM and its research should
ever be under-estimated. To this regard, one of our WP1  reviews
argely focused on the historical introduction of an important con-
ept in TCM (Zhao et al., 2012) and another article focused on the
alue chain analysis of herbal medicines, which is important for
he whole herbal medicine and food supplement trade and the
ndustry in general including its TCM sector. In our opinion, it rep-
esents an area overlooked by the scientiﬁc community (Booker
t al., 2012). Finally, due to the rich herbal resources that TCM is to
ffer (Wang et al., 2008), the popularity of acupuncture in Europe
nd the difﬁculty for Europeans to understand some fundamen-
al terminology and concepts of TCM, the FP7 GP-TCM consortium
tarted by focusing on two relatively mature areas of TCM, i.e. CHM
nd acupuncture, in its limited three years of life span. However,
e do acknowledge that TCM does not equal to “herbs and nee-
les” and both CHM and acupuncture might well need be used
nd studied as guided by TCM theories and principles. In the past
hree years, the consortium has incorporated a re-education pro-
ramme  into our newsletters and consortium activities, so that
ore and more consortium members have come to realise the
mportance of the personalised and holistic features of TCM and
ts perfect match in principles with modern systems science (van
er Greef and McBurney, 2005; van der Greef, 2011). As a contin-
ation of this re-education effort, we have invited a review that
ntroduces concepts widely used in TCM diagnosis and that espe-
ially focuses on TCM syndrome differentiation and its importance
n modern TCM research (Jiang et al., 2012). Despite any expected
ifﬁculties in absorbing the terms and concepts by the ﬁrst reading,
eaders of Journal of Ethnopharmacology and GP-TCM members are
ncouraged to read on in order to be rewarded by a more in-depth
nderstanding of TCM, its philosophy and clinical practice.
. The “GP-TCM Grand Issues” survey
.1. A survey towards consortium-wide conclusions
In order to draw conclusions regarding issues of the greatest
mportance to the broadest ﬁeld of TCM research, we  believed it
ssential not only to integrate opinions of individual WPs, but also
o break the barriers between WPs  and even between GP-TCM and
he other communities. Based on such considerations, an opinion
oll open to all consortium members and non-members was  con-
ucted to identify the most important priorities, challenges and
pportunities in TCM research. This approach helped us better
nderstand and interpret the major issues, directly or indirectly
elated to TCM research, both in the view of consortium mem-
ers and relevant non-members. In the following sub-sections, we
ummarise the survey methodology, outcomes and implications.
.2. Survey design
The survey was ﬁrst proposed by the management team
f the consortium, according to information and feedback col-
ected from members during the past two years. From June until
id-August 2011, a pre-survey study was conducted among all
P-TCM members to identify and accumulate “grand priority”,
grand challenge” and “grand opportunity” candidates. Twenty-ﬁve
onsortium members provided further inputs based on their per-
pectives, leading to the creation of candidate lists for all the three
grand issues”. Some members argued that, although the primary
ocus of the survey was TCM research, it would be better to include
ssues directly related to TCM research and those which could pro-
oundly affect TCM research, e.g. EU-China relations, national and
nternational policies, education, training and qualiﬁcation of TCMmacology 140 (2012) 458– 468 463
practitioners, etc. Their opinions were adopted so that all nomi-
nated items were included in this survey. The study was followed
by a full online survey entitled Grand Issues in Traditional Chinese
Medicine Research. Consortium members were invited to take part
in this anonymous survey. In addition, the survey team contacted
18 national and international societies with various focuses such as
TCM, acupuncture, pharmacognosy, complementary medicine and
phytochemistry, for their support to circulate the survey among
their members, of which 13 replied positively (please see the
Acknowledgments section for further details).
The invitation and the online survey were both supplemented
with brief information about the consortium and the aims of the
survey. The SurveyMonkey website was used to create and host
the survey. In addition to the English version, the survey was
also translated into Chinese to support Chinese-speaking partici-
pants. Preview-mode survey samples in English and Chinese were
archived, as shown in Supplementary materials 3 and 4.
The participants were advised that the aim of the survey was
to form a consensus on the “grand issues” in the context of the
broadest ﬁeld of TCM research. To achieve this, participants were
asked to choose a minimum of 5 and a maximum of 15 from each
candidate list to help determine the ﬁnal list of “top priorities”, “top
challenges” and “top opportunities”. An automatic randomisation
of candidate items was conducted before every survey to prevent
biased choices based on the given orders.
3.3. Outcomes and conclusions of the survey
3.3.1. Who  completed the survey?
A total of 187 questionnaires (156 in English and 31 in Chinese)
were completed and analysed. Respondents taking part in the sur-
vey were divided into 2 main categories: (a) 77 GP-TCM members,
including both beneﬁciary and non-beneﬁciary members, account-
ing for 41% of all participants and (b) 110 external participants,
accounted for 59% of all participants.
GP-TCM member and external participants both had a gender
(female/male) ratio of around 4/6. 52% GP-TCM member par-
ticipants and 32% external participants were ≥50 years of age
(Supplementary Fig. 3.1). As GP-TCM was mainly an EU-China col-
laboration, not surprisingly, most GP-TCM member participants
were based in either China (34%) or EU member states, including
UK (25%), Germany (7%), Italy (7%), Austria (5%), Spain (4%) and the
Netherlands (3%). Outside China and the EU, only USA contributed
≥3% of the questionnaires in the group. In contrast, in the external
participant group, although China (31%) and two  EU member states
UK (36%) and Germany (4%) remained main contributors, ﬁve coun-
tries outside EU and China contributed ≥3% of the questionnaires
in the group, including USA (6%), Canada (4%), Australia (3%), India
(3%) and Switzerland (3%).
As shown in Supplementary Fig. 3.3,  GP-TCM participants were
more evenly distributed regarding their expertise and educa-
tional background, with experts in pharmacology (10%), TCM,
including herbal medicine and acupuncture (9%), pharmacognosy
(9%), biology (8%), molecular biology (8%), botany (6%), cell biol-
ogy (6%), pharmacy (5%), pharmaceutical R&D (5%), TCM and
Western medicine (5%), Western medicine (3%), bioengineering
3%, taxonomy (2%), as well as omics technologies, includ-
ing metabolomics/metabonomics (4%), genomics/transcriptomics
(2%), proteomics (2%) and systems biology (3%), etc. These partic-
ipants were exposed to GP-TCM discussions in the past two years
and were familiar with omics and other technologies involved in
this survey, even if they were not omics experts. In contrast, dis-
tribution of expertise of external participants was  less even, with
28% participants being specialised in TCM practice, leading to a
possible bias of the view of this group towards the opinions of
TCM practitioners. Although 1–4% of external participants claimed
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mics and/or systems biology background, as a group they would be
ess familiar with the focused technologies of the GP-TCM consor-
ium, such as omics, because these participants were not exposed
o GP-TCM discussions.
.3.2. Grand priorities, challenges and opportunities
As shown in Supplementary Tables 3.1–3.3,  we were able to
ollect more priority and challenge candidates (N = 28 and N = 35,
espectively) than opportunity candidates (N = 18), indicating that
CM research faced more challenges and urgent scientiﬁc questions
han what could possibly be argued as opportunities. This implied
hat TCM research remained an emerging area and urgently needed
reater support to create more opportunities.
Based on survey outcomes, the grand priorities, challenges and
pportunities agreed by at least 50% GP-TCM member and/or
xternal participants are shown in Tables 3.1, 3.2 and 3.3,  respec-
ively. The tables list grand issues in decreasing order of votes
eceived from GP-TCM members, in comparison to those by exter-
al participants. Full lists of the survey outcomes are provided in
upplementary Tables 3.1–3.3.
.3.3. Data interpretation
.3.3.1. General conclusions. Both the GP-TCM member group and
he external participant group agreed on ﬁve grand opportunities,
hree grand priorities, but interestingly, these two  groups did not
ave any consensus on grand challenges.
GP-TCM member participants tended to achieve more consen-
us than the external participants did. In addition to the three grand
riorities agreed by both groups of participants, GP-TCM members
greed on seven more priorities and external participants agreed on
n additional three items. Although the two groups did not achieve
onsensus on grand challenges, GP-TCM member participants did
gree on four grand challenges, but external participants agreed
n only one. Finally, besides the ﬁve grand opportunities agreed by
oth groups, GP-TCM members agreed on additional ﬁve but exter-
al participants agreed on only one. This could be explained by the
act that GP-TCM member participants were a more balanced group
hat were more familiar with the speciﬁc research area, for which
onsensus was easier to be achieved. In this regard, the GP-TCM
ad achieved one of its objectives, i.e. to ﬁnd common ground for
his emerging area through building and training a balanced team,
acilitating networking, learning and discussion in order to increase
onsensus, while respecting differences.
The opinions of these two groups varied mainly at the following
spects: (i) any items involving specialist terms, which were not
xplained in detail in the survey, such as “omics”, “pharmacovig-
lance”, “GP-TCM” were ranked highly among GP-TCM member
articipants, but not by the external participants. This is to be
xpected since people could not vote for things that they were not
amiliar to, because they did not know if they were important or
ot; (ii) GP-TCM members’ ranking gave more attention to items
elated to research, because GP-TCM is a consortium focused on
CM research; (iii) external members voted for research but also
ighly ranked items that were not directly related to research but
evertheless would also affect research indirectly. This was because
e asked participants to vote for “grand issues” of greatest impor-
ance to TCM research, directly or indirectly. Thus, opinions from
xternal participants should serve as an excellent complement to
he views of consortium members. Views of the two groups should
oth be given serious consideration in the future.
.3.3.2. What was agreed by both GP-TCM member and external
articipants?. As shown in Table 3.1,  both groups agreed that
igh-quality research on efﬁcacy/effectiveness and mechanisms of
ction of CHM and acupuncture, as well as identiﬁcation of prior-
ty disease areas where TCM could achieve better outcomes weremacology 140 (2012) 458– 468
grand priorities. These results indicated that there was a clear con-
sensus on the need to acquire high-quality evidence to conclude on
if and how TCM could offer beneﬁts.
The lack of consensus between the two  groups on grand chal-
lenges was one of the most intriguing ﬁndings of this survey. This
implied that, although the GP-TCM consortium could recommend
grand challenges, it would take efforts to disseminate, interpret the
recommendations, collect feedback and make reﬁnements in order
to increase consensus and unite more stakeholders to tackle these
challenges together.
While both groups generally agreed that TCM knowledge
offered grand opportunities, they further agreed that the top oppor-
tunity was likely offered by TCM contribution to the management
of one of EU’s top healthcare challenges, i.e. long-term conditions
and chronic diseases (Table 3.3). They also agreed that combined
use of drugs from both TCM and Western medicine and the recent
huge funding to support TCM and biotech research in China should
offer opportunities. In particular, openness and readiness for EU
and China to jointly fund clinical studies were singled out as an
opportunity to watch.
3.3.3.3. What was agreed by GP-TCM members only?. As shown in
Table 3.1,  the consensus of the two  groups on the need for high-
quality research on efﬁcacy and mechanisms of action of TCM was
logically linked to two  grand priorities agreed by the GP-TCM mem-
ber group, i.e. “developing EU-China joint centres, initiatives and
adventures focused on TCM and CMMs”  and “cutting edge TCM
and CHP research using omics and systems biology technology”.
These could be interpreted as the answers from the consortium on
how high-quality research on efﬁcacy and mechanisms could be
achieved. Interestingly, three quality- and safety-related issues, i.e.
“high-quality research to evaluate the quality and safety of CHM”
and “quality control for commonly used CMMs”  and “pharmacovig-
ilance and safety of CMMs”  were prioritised by GP-TCM member
participants, but were only moderately voted by external partici-
pants. These discrepancies reﬂected the emphasis of the GP-TCM
consortium on quality of CMMs  and their safe use, in spite of the
general conﬁdence of TCM practitioners and relevant stakehold-
ers in the clinical safety proﬁle of CMMs.  Of note, the toxicology
work package of the GP-TCM consortium (WP3) especially focused
on chronic toxicity, which might not be readily noticeable by TCM
practitioners but could be identiﬁed by systemic clinical pharma-
covigilance (Ouedraogo et al., 2012; Shaw et al., 2012; Zhang et al.,
2012). 50–51% GP-TCM member participants also emphasised the
importance of rational use of medicinal plants and constructing a
comprehensive TCM literature database, which were supported by
slightly fewer than half external participants (43–45%).
For GP-TCM member participants, quality control of CMMs and
CHPs and pharmacovigilance of CHPs were not only grand priori-
ties but also grand challenges. Quality control of CMMs  and CHPs
posed a grand challenge thanks to their complexity, which made
them unsuitable for quality assurance by methodologies used for
conventional drugs. Clinical pharmacovigilance of CHPs also posed
as a grand challenge as it needed a fully functioning adverse event
report network, qualiﬁed experts and funding for data integration
and analysis, which were not fully established yet worldwide, as
reviewed by WP3  (Shaw et al., 2012; Zhang et al., 2012). TCM man-
agement of chronic diseases, a grand opportunity agreed by both
groups, was also regarded a grand challenge by GP-TCM member
participants, because efﬁcacy studies of CMM/CHP in chronic dis-
eases usually needed long duration of observation and there were
still many unsolved problems in clinical trials of CHM and CHPs,
including decoctions and granules (Flower et al., 2012; Luo et al.,
2012). Noticeably, lack of European funding for TCM research was
singled out as a grand challenge for the European TCM scientiﬁc
community as there was no funding yet dedicated to TCM research
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Table 3.1
Grand priorities agreed by both GP-TCM members and external participants, or recommended by either GP-TCM members or external participants only.
Ranking Grand priorities
By GP-TCM members (N = 77) By external participants
(N = 110)
Order Vote Order Vote
Priorities agreed by both GP-TCM members and external participants
2  71% 3 60% High-quality clinical efﬁcacy and effectiveness studies of
CHM and acupuncture
3 59%  5 56% High-quality research to demonstrate the mechanisms of
action of CHM and acupuncture
3  59% 2 60% Identify priority (disease) areas where TCM is likely to
achieve better outcomes for patients and the society
Priorities recommended by GP-TCM members only
1 72% 7 49% High-quality research to evaluate the quality and safety of
CHM, due to recent and frequent misidentiﬁcation,
adulteration and contamination of CHPs
3  59% 18 33% Taking advantage of the EU-China dialogue channels
strengthened through the FP7 GP-TCM Consortium and
other consortiums, organisations and societies, develop
EU-China joint centres, initiatives and adventures focused
on  TCM and CMM products
6  58% 11 44% Quality control for those CMMs  which were widely used in
clinics
7 54%  18 33% Taking advantage of the maturing omics technology and
emerging systems biology methodologies, carry out
cutting-edge TCM and CHP research
8  53% 15 40% Pharmacovigilance and safety of CMMs
9  51% 12 43% Special attention should be paid to rational use of Chinese
medicinal plants, especially those endangered plants, in
order to keep sustainable use, maintain biodiversity and
protect our environment
10  50% 10 45% Database for compiling all relevant information about
TCM. Such a database would provide critical information
to interested groups according to a priority topics as well
as a tool to centralise all available scientiﬁc literature or
documents
Priorities only recommended by external participants
11 49%  4 59% CHM and acupuncture in prevention and treatment of
chronic diseases
12  47% 6 55% Upgraded EU funding and pool funding from a variety of
sources to build international research collaborations to
support evidence-based clinical and basic research on
some maturing areas of TCM, including CMM  products
18  36% 1 68% Development of a national policy for TCM supporting the
integration of TCM into mainstream health care system,
especially in the primary care system. An important
requirement is the inclusion of herbal medicine as
essential drugs into the health insurance package
Table 3.2
Grand challenges agreed by both GP-TCM members and external participants, or recommended by either GP-TCM members or external participants only.
Ranking Grand challenges
GP-TCM members (N = 77) External participants (N = 110)
Order Vote Order Vote
Challenges agreed by both GP-TCM members and external participants
None
Challenges recommended by GP-TCM members only
1  63% 4 44% Quality control of CMMs  and CHPs
2  51% 3 46% Lack of European funding for TCM research,
compared to the circumstances in China and
the USA
3  50% 5 43% Focus on TCM research of certain chronic
diseases and conditions, where TCM has
established a good track record of clinical
efﬁcacy by using scientiﬁc methods to provide
scientiﬁc evidence for efﬁcacy
3  50% 23 26% Pharmacovigilance of CHPs
Challenges only agreed by external participants
13 36% 1 51% Regulation of TCM practitioners in the EU
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Table 3.3
Grand opportunities agreed by both GP-TCM members and external participants, or recommended by either GP-TCM members or external participants only.
Ranking Grand opportunities
By GP-TCM members (N = 77) By external participants
(N = 110)
Order Vote Order Vote
Opportunities agreed by both GP-TCM members and external participants
1 75%  1 82% Long-term conditions and chronic diseases are top
challenges for Europe and TCM might offer potentially
useful knowledge on these diseases and conditions,
including ageing, infectious disease, diabetes and obesity
3  55% 4 57% Potentially positive or negative effects of drug
combinations from both systems needs to be established
4 54%  3 60% Openness and readiness for EU and China to jointly fund
clinical studies including trials and observational studies in
both countries/locations
6  53% 6 51% Chinese government recently announced a $308 billion
biotech industry expansion scheme to create one million
new biotech jobs in 2015. EU has to come up with new
policy and funding initiatives to promote biotech industry
especially TCM or herbal medicine projects to attract
Chinese partners and investments
9  50% 2 64% Knowledge accumulated through thousands of years of
TCM clinical experience provides rich resources for
knowledge transfer/education and for understanding and
integration of Western and Eastern ideals. The knowledge
transfer should eventually beneﬁt healthcare and
pharmaceutical industry and education should not be
restricted to scientists, it should include industry, the
regulators, charities and the public
Opportunities recommended by GP-TCM members only
2  57% 16 37% Maturing omics and improving systems biology
methodologies have offered powerful tools to interpret the
complexity and holism of CMM  and TCM
4  54% 18 28% With the FP7 GP-TCM funding, an EU-China collaborating
forum has been established and good practice guidelines
have started to be developed
6  53% 8 45% Bridging the gap between modern personalised health
(including sub-health condition) and personalised TCM
diagnosis and treatment using omics and systems biology
8  51% 17 33% Network based pharmacological evaluation for CMMs
9  50% 14 39% China’s open policy and ever increasing funding to
scientists in China create good collaborating opportunities
55% 
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iOpportunities recommended by external participants only
11 49% 5 
n Europe, in contrast to the federal funding dedicated to research
f complementary medicines (including TCM) by the US National
entre for Complementary and Alternative Medicines, and the rich,
till rapidly increasing, funding into TCM research by a number of
ainstream Chinese funders.
GP-TCM member participants voted conﬁdence in maturing
mics and improving systems biology methodologies as powerful
ools to interpret the complexity and holism of CMM  and TCM, as
ell as bridging TCM with modern personalised health. This conﬁ-
ence was based on their literature analyses on the state of the art
f omics studies of in vitro and in vivo pharmacology (Buriani et al.,
012), regulatory science (Pelkonen et al., 2012) and acupuncture
Jia et al., 2012). GP-TCM member participants also voted con-
dence in the opportunities offered by the collaboration forum
nd good practice guidelines established by the GP-TCM consor-
ium and this conﬁdence was clearly encouraging and required for
he healthy development of TCM research in Europe. In addition,
P-TCM member participants ranked network based pharmaco-
ogical evaluation (i.e. network pharmacology) (Hopkins, 2008;
insworth, 2011) and China’s open policy and increasing funding
n China grand opportunities, as these would offer new research
trategies and create even stronger collaborators.
.3.3.4. What was agreed by external participants only?. As shown
n Table 3.1,  external participants gave top priority to “supportInternational cooperation on clinical trial for marketed
CMMs
integrating TCM into mainstream health care system”, with 67.6%
vote of conﬁdence as a grand priority. In contrast, this item only
attracted votes from 34.7% GP-TCM member participants. This
might reﬂect the gap between the wish of many TCM practitioners,
who  were the largest subgroup among external participants, and
the more objective and realistic votes by scientists, who  comprised
the biggest part in the GP-TCM consortium. Echoing GP-TCM’s
appeal for the challenges posed by lack of funding in Europe, exter-
nal participants also acknowledged the importance of funding in
TCM research, regarding it as a priority to pool funding from various
sources to support international collaborations. Echoing the agree-
ment by both groups on TCM treatment of chronic diseases as a
grand opportunity TCM could offer (Table 3.1), 59% external partic-
ipants and slightly fewer than half GP-TCM member participants
(49%) also recommended TCM treatment of chronic diseases as a
priority for future TCM research. Similarly, “international coopera-
tion on clinical trials for marketed CMMs”  received 55% of vote from
external participants, while slightly fewer than half GP-TCM mem-
ber participants (49%) recommended this item as an opportunity
for future TCM research.
External participants did not achieve much consensus on what
were the grand challenges in TCM research. Only “regulation of TCM
practitioners in the EU” received more than half votes (51%) and
became the only grand challenge agreed by this group. As regula-
tion of CHP had recently been updated (Fan et al., 2012), regulation
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f practitioners clearly would have a profound impact on the TCM
ndustry and also indirectly on TCM research.
. Conclusions
One of the biggest achievements of the consortium was putting
ogether an open-start, open-ending consortium, which grew con-
tantly in terms of membership size, geographical coverage, as well
s its diversity and size of external expertise pool. A relatively bal-
nced team with a variety of expertise needed for studies of CHM
nd acupuncture using modern technologies, especially omics and
ystems biology, has been developed. While the consortium grew,
he focus on good practice, TCM and research has remained.
Another achievement was that the consortium has systemi-
ally instigated fruitful discussions on various specialist areas of
CM research. The consortium reached agreement on guidelines for
eviewing and publishing TCM literature, naming and authentica-
ion of medical plants, evaluating the impact of different extraction
ethods in TCM clinical practice and in research, and for con-
ucting clinical trials on CHM. It also compiled a comprehensive
omparison of global regulation on CHM and CHP. The consortium
tudied the state of the art of CHM and acupuncture research and
aid keen attention to the application of omics and systems biology
ethodologies in TCM research. Clearly, the mission and aims of the
onsortium, which are very much shared with sister organisations
uch as CGCM, needs to be continued beyond the lifespan of FP7
P-TCM. Close collaborations should therefore be forged between
nterested organisations in order to avoid duplicating effort and to
roduce a greater impact by working together.
It appears that, although the application of omics and systems
iology in TCM research, development and regulation is still in its
nfancy, it holds great promise. This conﬁdence was  reﬂected by
he opinions of GP-TCM members in the “Grand Issues” survey
nd supported by the recent research developments reviewed in
his special issue (Buriani et al., 2012; Jia et al., 2012; Pelkonen
t al., 2012). Nevertheless, studies using omics and systems biology
pproaches should be particularly good at generating new hypothe-
es on mechanisms for the effects of TCM and these hypotheses
ould need many additional approaches to substantiate them.
Looking forward, prospects for the whole area largely depend
n how experts in different disciplines and stakeholders in differ-
nt regions and sectors collaborate and how much funding will be
nvested into this ﬁeld. Without closer collaboration and signiﬁ-
ant investment, this emerging area of scientiﬁc research, which
as direct relevance to the wellbeing of our citizens and holds
romise for reforming some of our current healthcare models, could
ither. However, the consortium remains cautiously optimistic
hat through interdisciplinary, interregional and intersectoral col-
aborations, we should be in a position to convince stakeholders in
ifferent sectors to join forces in this promising area. To coordinate
ollaborations after the lifespan of the FP7 GP-TCM consortium, a
ew interest group, temporarily known as “The GP-TCM Research
ssociation” or “The Good Practice in Traditional Chinese Medicine
esearch Association” would relay the baton of GP-TCM, to:
Maintain the interactive network established by GP-TCM.
Continue to organise research, discussion, dissemination and
implementation of good practice in TCM research and develop-
ment.
Establish high-quality evidence based research and development
in TCM.
Promote collaborations and sharing of resources, expertise and
good practice among members.
Promote collaborations with existing relevant societies, consortia
and organisations.macology 140 (2012) 458– 468 467
• Promote interdisciplinary, international and intersectoral collab-
orations in TCM research and development.
• Promote good practice in publishing TCM research and develop-
ment outcomes.
• Promote dissemination of scientiﬁc research and development
outcomes to stakeholders and relevant industry and professional
groups.
• Compile and compare updated regulatory policies in different
areas of the world to share with stakeholders and the public,
helping the best TCM products to enter the international market.
• Promote outreach of scientiﬁc outcomes and latest developments
in regulatory sciences to the public and end users of TCM to safe-
guard the wellbeing of the people around the world.
In summary, the FP7 GP-TCM project has taught us that it is
neither easy to reach consensus on the deﬁnition and details of
good practice, nor to agree on lists of grand priorities, challenges
and opportunities, although it is much needed for the development
of high-quality TCM research. It will be even more difﬁcult to agree
on how to address each grand issue and eventually to have it done.
Nevertheless, as Madam Marie Curie said, “Nothing in life is to be
feared, it is only to be understood. Now is the time to understand
more, so that we  may  fear less”.
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